BACKGROUND: Novel fusion transcripts (FTs) caused by chromosomal rearrangement are common factors in the development of cancers. In the current study, the authors used massively parallel RNA sequencing to identify new FTs in colon cancers. METHODS: RNA sequencing (RNA-Seq) and TopHat-Fusion were used to identify new FTs in colon cancers. The authors then investigated whether the novel FT nuclear receptor subfamily 5, group A, member 2 (NR5A2)-Kelch-like family member 29 FT (KLHL29FT) was transcribed from a genomic chromosomal rearrangement. Next, the expression of NR5A2-KLHL29FT was measured by quantitative realtime polymerase chain reaction in colon cancers and matched corresponding normal epithelia. RESULTS: The authors identified the FT NR5A2-KLHL29FT in normal and cancerous epithelia. While investigating this transcript, it was unexpectedly found that it was due to an uncharacterized polymorphic germline insertion of the NR5A2 sequence from chromosome 1 into the KLHL29 locus at chromosome 2, rather than a chromosomal rearrangement. This germline insertion, which occurred at a population frequency of 0.40, appeared to bear no relationship to cancer development. Moreover, expression of NR5A2-KLHL29FT was validated in RNA specimens from samples with insertions of NR5A2 at the KLHL29 gene locus, but not from samples without this insertion. It is interesting to note that NR5A2-KLH29FT expression levels were significantly lower in colon cancers than in matched normal colonic epithelia (P 5.029), suggesting the potential participation of NR5A2-KLHL29FT in the origin or progression of this tumor type. CONCLUSIONS: NR5A2-KLHL29FT was generated from a polymorphism insertion of the NR5A2 sequence into the KLHL29 locus. NR5A2-KLHL29FT may influence the origin or progression of colon cancer. Moreover, researchers should be aware that similar FTs may occur due to transchromosomal insertions that are not correctly annotated in genome databases, especially with current assembly algorithms. Cancer 2017;123:1507-15.
INTRODUCTION
Colorectal cancer is the third most frequent cancer type worldwide. 1 Although the diagnosis and treatment of colorectal cancer have progressed rapidly, the overall 5-year survival rate remains low. 2 To the best of our knowledge, the underlying molecular mechanisms causing this high incidence and poor prognosis have not yet been fully elucidated.
Cancer-related genetic alterations include amplification, deletion, duplication, and chromosomal rearrangement (chromosome translocation, inversion, and deletion). These aberrations can exert potent impacts on the development or progression of cancer. 3, 4 Gene fusions commonly are caused by chromosomal rearrangement. Many gene fusions have been identified in leukemias, lymphomas, and sarcomas, with the BCR-ABL fusion gene observed in patients with chronic leukemia being a notable example. 5, 6 In recent decades, gene fusions also have been discovered in epithelial cancers, including TMPRSS2-ERG in patients with prostate cancer and EML4-ALK in individuals with non-small cell lung cancer. [7] [8] [9] For many years, gene fusions in epithelial cancers were not identified, possibly due to difficulties in detecting chromosomal aberrations in the chaotic karyotypic profiles typical of solid tumors. 10 Next-generation, whole-genome sequencing can identify chromosomal rearrangements. However, this method is expensive, inefficient, and tedious for discovering oncogenic fusion gene events because only a fraction of chromosomal rearrangements generate fusion messenger RNA (mRNA). In contrast, massively parallel RNA sequencing (RNA-Seq) can directly identify only those fusion genes that produce transcripts, thereby providing an efficient approach with which to discover gene fusions. 10 Various algorithms have been used to detect gene fusions in RNA-Seq data sets. TopHat-Fusion is a new algorithm developed to identify fusions. 11 This method is advantageous for finding novel splice variants and novel gene fusions because it detects individual and paired reads spanning a fusion point, and does not rely on existing annotation.
Currently, several fusion transcripts (FTs) have been shown to occur during colorectal carcinogenesis, including C2orf44-AKL, VTI1A-TCF7L2, NAV2-TCF7L1, EIF3E-RSPO2, PTPRK-RSPO3, and LACTB2-NCOA2. [12] [13] [14] [15] In the current study, we used TopHatFusion to identify novel FTs caused by chromosomal rearrangements in patients with colon cancers. We found a previously undescribed fusion gene transcript resulting from an insertion at the Kelch-like family member 29 (KLHL29) gene locus. This fusion gene transcript was not tumor-specific and was expressed in all individuals with the genomic DNA KLHL29 insertion. It is interesting to note that downregulation of this FT was observed in patients with colon cancers.
MATERIALS AND METHODS

Tissue and Plasma Specimens
In the current study, colon cancer samples and corresponding normal colon epithelia were obtained at the time of colonoscopy, whereas gastric cancer samples were obtained at the time of endoscopy. Plasma samples were collected from noncancer and cancer populations. Samples from Japanese patients with gastric cancer were obtained at the time of endoscopy in Japan. All patients and normal populations provided written informed consent under protocols approved by the Institutional Review Boards at The Johns Hopkins University School of Medicine, The University of Maryland, and Tohoku University in Japan. All specimens were stored in liquid nitrogen or at -808C until DNA or RNA extraction.
DNA and RNA Extraction
Genomic DNA was isolated from tissues and plasma samples using a DNeasy Tissue Kit (Qiagen, Gaithersburg, Md) according to the manufacturer's instructions. Total RNA was extracted from tissues using TRIzol reagent (Invitrogen, Carlsbad, Calif). DNA and RNA specimens were stored at -808C before analysis.
Next-Generation RNA-Seq RNA-Seq was performed according to existing protocols at the SKGCC core facility. TopHat-Fusion was used to analyze RNA-Seq data from colonic tissues to detect new FTs. TopHat-Fusion consists of 2 steps: 1) alignment and 2) identification of FTs. TopHat2 (version 2.0.10) was used to align RNA-Seq reads to the human reference genome (GRCh37) (parameters: -p 12-segment-mismatches 2-fusion-min-dist 100000-fusion-anchor-length 13-max-intron-length 100000-r 0 -mate-std-dev 80-fusion-ignorechromosomes MT) and tophat-fusion-post (parameters: -p 12-num-fusion-reads 2 -num-fusion-pairs 0), which is included in the TopHat2 package, was used to identify FTs from the TopHat2 alignments. Further details regarding the TopHat-Fusion method have been described previously. 11 The read length was 75 base pairs (bp). In addition, TopHat-Fusion also was used to detect the new FT in the ENCODE (Encyclopedia of DNA Elements) public RNA-Seq data set from 135 experiments.
Genomic DNA Polymerase Chain Reaction DNA specimens were amplified using the Platinum Taq DNA polymerase kit (Invitrogen). The 20-lL reaction volume contains 10 ng of DNA, 2 l of 10xBuffer, 0.4 lL of 10mM d-NTP, 0.6 lL of 50-mM MgCl 2 , 0.2 lL of Taq polymerase, 0.4 lL of forward and reverse primers (10 lM), and water. The reaction conditions were 958C for 30 seconds, 35 cycles at 958C for 30 seconds, 608C for 45 seconds, and 728C for 1 minute, followed by final elongation at 728C for 10 minutes and storage at 48C. The primers are shown in Supporting Information Table  S1 . Polymerase chain reaction (PCR) products were loaded onto 1.5% agarose gels, stained with ethidium bromide, and visualized under an ultraviolet Luminescent Image Analyzer (LAS-4000 Mini; GE Healthcare Life Sciences, Pittsburgh, Pa).
Quantitative Real-Time PCR During extraction of RNA from colon cancer and matched normal colon epithelia, DNAase (Invitrogen)
Original Article was used to digest potential contaminating DNA. Random real-time (RT) primers and SYBR Green Supermix (Bio-Rad Laboratory, Hercules, Calif) were used to perform 2-step quantitative RT-PCR (qRT-PCR) as described previously. 16 The primers for the new fusion transcript and internal control (glyceraldehyde 3-phosphate dehydrogenase [GAPDH]) are described in Supporting Information Table S1 . Gene expression levels of the novel FT were normalized to GAPDH expression.
TOPO Cloning Reaction and Sanger Sequencing
PCR products were cloned into a TOPO vector and amplified using a TOPO Cloning TM Kit (Invitrogen) according to the manufacturer's instructions. Specifically, PCR products were ligated to the TOPO vector and transformed in Escherichia coli DH5a by heat shock. Transformed cells were spread on LB agar plates with 50 lL/mL of ampicillin and incubated overnight at 378C. Transformants were selected and recombinant plasmids were extracted using a Plasmid Miniprep Kit (Qiagen). Recombinant plasmids were then sent to the Genetic Resources Core Facility at The Johns Hopkins University School of Medicine for Sanger sequencing.
Statistical Analyses
Relative expression levels of the FT between cancer and matched normal colonic epithelia groups were evaluated using the 2-tailed Student t test. The insertion rate in different groups was analyzed using the chi-squared test. A P value <.05 was considered to be statistically significant. All statistical analyses were performed using SPSS statistical software (version 19.0; IBM Corporation Armonk, NY).
RESULTS
Next-Generation RNA-Seq and Genomic Analysis Detect a Novel FT (NR5A2-KLHL29FT) in Normal Colon Epithelia By using TopHat-Fusion alignment to analyze RNA-Seq data from matched colon cancer and corresponding normal colon epithelia samples, only 1 normal colon epithelium (sample 1N) was found to contain FTs, whereas other samples did not demonstrate any FTs due to either no new FTs or low read levels. In the normal colon epithelium (sample 1N) that contained FTs, 11 candidate FTs were found, including 9 intrachromosomal and 2 interchromosomal FTs (see Supporting Information Table S2 ). These candidate FTs were reviewed according to the University of California at Santa Cruz (UCSC) genome database (hg38) and National Center for Biotechnology Information Basic Local Alignment Search Tool (NCBI BLAST). All intrachromosomal FTs appeared to span short distances and were considered to represent unknown (long) introns or read-through transcription, and therefore were not studied further. The 2 interchromosomal FTs occurred between chromosomes 5 and 12 and chromosomes 1 and 2, respectively. The FT between chromosomes 5 and 12 was deemed a falsepositive because this FT involved both the SUDS3 (suppressor of defective silencing 3 homolog) gene and a pseudogene of SUDS3, which have nearly identical sequences and could fool the aligner. Finally, the FT between chromosomes 1 and 2 was found to involve the sense strand of the nuclear receptor subfamily 5, group A, member 2 (NR5A2) gene on chromosome 1 and the antisense strand of the KLHL29 gene on chromosome 2 (NR5A2-KLHL29FT) and was chosen for further study (Fig. 1 ).
Validation of a Chromosomal Alteration (a Long Insertion, Rather Than a Chromosomal Rearrangement) in Clinical Samples
FTs are transcribed from genetic aberrations, specifically chromosomal rearrangements. 7 At first, we hypothesized that NR5A2-KLHL29FT was transcribed from a chromosomal rearrangement between chromosomes 1 and 2, with a breakpoint located in intron 4 of NR5A2 and intron 1 of KLHL29. The insertion site was only 175 bp away from KLHL29 exon 2, but much farther away from KLHL29 exon 1. A diagram of this hypothesized chromosomal rearrangement is shown in Figure 2A . We designed 4 pairs of primers to amplify products spanning the breakpoint of this chromosomal rearrangement (ie, the fusion point between NR5A2 and KLHL29) ( Fig. 2A ) (Supporting Information Table S1 ). However, only primer pairs 1 and 2 successfully amplified products covering the breakpoints, whereas primer pairs 3 and 4 failed to amplify any products using the same sample (1N) as the DNA template. Identical results were found in several additional samples, including DNA from colon tumor samples and from white blood cells from patients without cancer (Figs. 2B and 2C). Thus, we hypothesized that DNA abnormalities could not have resulted from complete rearrangement of chromosomes 1 and 2. The genomic DNA statuses of wild-type NR5A2 and wild-type KLHL29 were assessed using additional primers flanking the breakpoint in these 2 genes (see Supporting Information Table S1 ). As shown in Figure 2B , NR5A2 manifested only 1 wild-type genotype in all samples, whereas KLHL29 demonstrated 2 alleles (1 large band and 1 small band) and 3 possible genotypes (homozygous large band, heterozygous large-small bands, or homozygous small bands) in various patient samples. Every sample with products using primer pair 1/2 had at least 1 large allele of KLHL29. These results led to a new hypothesis, namely that KLHL29 had 2 types of alleles as a germline polymorphism: one, the wild-type KLHL29 allele, corresponded to genome references in the UCSC database (hg38) and the second, a previously undescribed KLHL29 allele, resulted from an insertion of part of the NR5A2 gene (Fig. 2D) . In the interim, KLHL29 genotypes were predicted to be of 3 types: homozygous insertion, heterozygous insertion, or homozygous wild-type.
To discover the exact sequence of the partial NR5A2 insertion into the KLHL29 gene, we separated several large and small KLHL29 bands amplified from different patients, using the KLHL29 gene primers flanking the fusion site, and then performed TOPO cloning and Sanger sequencing. All large bands contained the same sequence, indicating that a portion of NR5A2 (121 bp) had been inserted into KLHL29 at the breakpoint described above (Fig. 2D) . Meanwhile, NR5A2 products from all samples were identical to the sequence at the NR5A2 locus in the UCSC database (data not shown). Thus, this insertion represented a copy of part of NR5A2 intron 4 (from chromosome 1) inserted into KLHL29 intron 1 on chromosome 2. Because sample 1N was homozygous for the insertion at the KLHL29 locus, we reasoned that a new NR5A2-KLHL29 FT (NR5A2-KLHL29FT) had been detected by TopHat Fusion analysis, having been transcribed from the KLHL29 gene locus by an insertion of NR5A2 rather than from a chromosomal rearrangement. Using the NCBI BLAST, we did not find this insertion sequence at any other loci besides NR5A2 on chromosome 1, thereby demonstrating that it is a nonrepetitive insertion from the NR5A2 gene to the KLHL29 locus.
The Insertion Is Not Related to Cancer Prevalence and Thus It Represents a Common Polymorphism at the KLHL29 Gene Locus
According to the results presented above, the insertion was not a rare event at the KLHL29 gene locus in patients with cancer or in noncancer populations. Next, a larger cohort of samples, including 67 patients with colon cancer, 45 patients with gastric cancer, and 101 noncancer subjects, was evaluated to assess the prevalence of the insertion and its possible relevance to cancer risk. The polymorphism information content of this polymorphism was 0.321, and heterozygosity at this locus was 0.352. As described in Table 1 , neither the frequency nor the carriage rate of the insertion demonstrated any statistically significant difference between colon cancer, gastric cancer, and noncancer populations (P>.05). This result suggested that KLHL29 insertion is a common polymorphism that is not associated with cancer occurrence. However, both the carrier rate (66.7%) and the frequency rate (40.8%) of the insertion in Japanese patients with gastric cancer were significantly higher than in American patients with gastric cancer (43.3% and 23.1%) or American noncancer populations (41.6% and 22.8%) (P <.01). This phenomenon suggests that the insertion is more frequent in Asian populations, or possibly that this insertion originally arose in ancient Asian populations and conferred an evolutionary advantage of some sort. However, this hypothesis needs to be verified by additional multi-institutional studies to assess this polymorphic insertion in the future. 
Validation of NR5A2-KLHL29FT on RNA Levels in Clinical Samples
We then proceeded to validate the existence of NR5A2-KLHL29FT in sample 1N (normal colon epithelium). After eliminating potential residual DNA using DNase (Invitrogen) in RNA, we performed RT-PCR using primer 1 (Supporting Information Table S1 ) and ran the products on gels. A clear band is shown in sample 1N. We also detected NR5A2-KLHL29FT in colon cancer (1T) matched to sample 1N (Fig. 3A) . Based on the presence of NR5A2-KLHL29FT in both tumor and normal cDNA, this FT was determined to be germline rather than tumorspecific. It is interesting to note that when qRT-PCR was performed to measure the expression of NR5A2-KLHL29FT, the expression level in colon cancer was lower than that in matched normal colon epithelium (2 Table  S3a ). Subsequently, matched colon cancer-normal colon epithelial pairs from 21 additional patients with colon cancer were enrolled to measure NR5A2-KLHL29FT expression by qRT-PCR. Only 14 matched cancer-normal colon epithelia cases were clearly detected with NR5A2- Figure 2 . Identification of nuclear receptor subfamily 5, group A, member 2 (NR5A2) sequence insertion at the Kelch-like family member 29 (KLHL29) gene locus. (A) It was hypothesized that there was a chromosomal rearrangement between the NR5A2 gene on chromosome 1 and the KLHL29 gene on chromosome 2. Four primer sets were generated to validate the fusion gene. (B) The fusion gene using primer set 1, the KLHL29 gene, and NR5A2 gene status were, respectively, studied in each sample. NR5A2 gene status was found to be the same in all the samples. The KLHL29 gene has 3 statuses: homozygous big band, heterozygous big band, and homozygous small band. Both samples with homozygous or heterozygous big band status demonstrated positive fusion bands. (C) Among primer sets 2, 3, and 4 amplifying the fusion gene, only primer set 2 worked, whereas the other 2 primer sets did not amplify any bands, suggesting the fused NR5A2 sequence was not so long. (D) Based on the analysis shown in panels B and C, it is believed that the fusion gene is a polymorphic insertion instead of chromosomal rearrangement. Using TOPO Cloning and Sanger sequencing, it was found that the insertion was the same in the different samples as shown here. bp indicates base pairs. KLHL29FT by a single peak on a melting curve, and confirmed by clear bands on gels (Fig. 3B ) (see Supporting Information Table S3a/b). It is interesting to note that all 14 of these matched pairs were positive for a KLHL29 insertion (homozygous or heterozygous for the insertion allele), whereas the remaining 7 pairs were homozygous wild-type. Based on these results, only samples containing the insertion, either homozygous or heterozygous, could express NR5A2-KLHL29FT. In addition, in all 15 matched colon cancer-normal colon epithelia pairs with expression of NR5A2-KLHL29FT (comprised of the sample 1N-1T pair and the additional 14 matched colon cancer-normal pairs), the expression level of NR5A2-KLHL29FT was decreased compared with normal colon epithelia in the majority of cases (11 of 15 cases; average fold-change of 0.23 [P5 .029]) (Fig. 3C ) (see Supporting Information Table S3a ). Thus, we concluded that NR5A2-KLHL29FT is only expressed in subjects with the KLHL29 insertion. We also speculated that when NR5A2-KLHL29FT is downregulated, colon carcinogenesis may be supported. However, this hypothesis requires further experimental evidence.
Analysis of RNA-Seq Data From a Public Database Using TopHat Fusion Alignment to Detect NR5A2-KLHL29FT
To confirm the prevalence of NR5A2-KLHL29FT in the general population, we reanalyzed the ENCODE public RNA-Seq data set from 135 experiments using TopHatFusion. It is interesting to note that the NR5A2-KLHL29 fusion was detected in only 2 of 135 cell lines, including ENCSR000AFK (described as thyroid gland/tissue/fetal) and ENCSR908ZAS (described as hepatocyte/in vitro differentiated cells/embryonic). The fusion point was exactly the same as what was detected in our first sample (sample 1N). Based on this analysis, the NR5A2-KLHL29FT FT does occur, but is not a common event in the ENCODE database. However, as described above, in our cohort of matched colon cancer-normal epithelia pairs, NR5A2-KLHL29FT was common and could be detected in all matched normal tissues containing the insertion. To explain this disparity, we rereviewed expression levels of NR5A2-KLHL29FT by qRT-PCR in the current study cohort (see Supporting Information Table  S3a ). We hypothesized that only samples with relatively high expression levels of NR5A2-KLHL29FT by qRT-PCR could be identified by TopHat Fusion, whereas samples with low expression levels could not.
DISCUSSION RNA-Seq has been used widely to identify novel FTs in individuals with cancer. 17, 18 We originally sought to detect novel FTs due to chromosomal rearrangements in colon cancers. To our surprise, a novel FT, NR5A2-KLHL29FT, was identified in a normal colon specimen (1N). In the process of validating this abnormality at the DNA level, NR5A2-KLHL29FT was unexpectedly shown to come from a polymorphic insertion at the KLHL29 locus and to be expressed in both cancer and normal samples. These unexpected results suggest that polymorphic insertion events at the DNA level represent a possible mechanism of novel FTs that is different from chromosomal rearrangement, being especially likely when novel FTs are identified in normal tissues by RNA-Seq. We speculate that both heterogeneous nuclear RNA and mature, fully processed mRNA could have been available for the construction of the RNA-Seq library, and that the reads shown in Figure 1 were derived from both of these classes of molecules. In such cases, primers amplifying longer products that span both ends of an insertion junction should be generated to verify its origin.
We also questioned how the nonrepetitive sequence of the NR5A2 gene could have become inserted into the KLHL29 gene. Retrotransposons, as transposable DNA elements, have the ability to duplicate themselves onto other regions of the genome. They mobilize in a "copyand-paste" manner involving reverse transcription of an RNA intermediate and insertion of its cDNA copy into a new locus. 19 Short interspersed elements (SINE, mainly Alu), long interspersed elements (LINE-1 or L1), and processed pseudogenes are 3 types of retrotransposons. However, both L1 and SINE are multiply-repeated mobile elements in the genome, whereas processed pseudogenes are characterized by a lack of introns. Thus, these 3 retrotransposons were unlikely mechanisms underlying the nonrepetitive segmental duplication found in the current study. L1-mediated 3 0 transduction can associate 3 0 flanking DNA sequences as read-through transcripts and mobilize nonrepetitive DNA sequences to a new genomic region. 20, 21 These nonrepetitive segmental duplications have some typical characteristics, including a poly-A tract, target site duplication flanking the insertion, and an L1 endonuclease site (5 0 -TTTT/AA-3 0 ). Nevertheless, our insertion at the KLHL29 gene locus did not exhibit these hallmarks of L1-mediated 3 0 transduction, thus excluding the possibility of L1-mediated insertion. Recently, Onozawa et al experimentally confirmed that DNA doublestrand breaks (DSBs) can be repaired via reverse transcription of an RNA template and insertion of cDNA, and they clinically validated the prevalence of polymorphic insertions related to DSBs using public databases. 22 Onozawa et al 22 classified unknown insertions lacking common hallmarks of L1-mediated events as class 2 templated sequence insertion polymorphisms, which were considered microhomology-mediated annealing of mRNA, reverse transcription, and healing of DNA DSBs induced by physiologic or environmental DNA damage. The insertion sequences at the KLHL29 locus in the current study have some microhomology, such as 5 0 flanking sequence (AATCCAC at the KLHL29 sense strand and AATCCAA at the NR5A2 sense strand with opposite direction) and 3 0 flanking sequence (A in both genes). Thus, we hypothesize that our insertion may be a class 2 templated sequence insertion polymorphism caused by a DSB repair mechanism, including reverse transcription of partial immature NR5A2 RNA and the insertion of the corresponding cDNA into the KLHL29 locus, with KLHL29 intron 1 experiencing DNA damage due to unknown factors.
The KLHL29 gene belongs to one member of the KLHL (Kelch-like) gene superfamily. 23 Four KLHL family members have been reported to be associated with cancers, including KLHL6 in chronic lymphocytic leukemia, KLHL19 in gallbladder and lung cancer, KLHL20 in prostate cancer, and KLHL37 in brain tumors. [24] [25] [26] [27] [28] To the best of our knowledge, there are no studies published to date regarding the KLHL29 gene, nor of the function of this polymorphic insertion at the KLHL29 locus. Polymorphic insertions are associated with some diseases. 29 One example is the polymorphic insertion of varying numbers of an 86-bp tandem repeat in interleukin-1 receptor antagonist (IL-1RA) intron 2. By comparing differences in IL-1RA frequency in various groups, allele 2 of the IL-1RA gene (IL1RN*2) has been shown to be associated with ulcerative colitis and Crohn disease, systemic lupus erythematosus, and other illnesses. [30] [31] [32] Thus, we studied whether KLHL29 insertion polymorphism was associated with colon cancer. However, we did not find any difference in the frequency or carrier rate of the insertion between noncancer and colon cancer cohorts. In addition, the insertion polymorphism was not found to be correlated with gastric cancer occurrence. Based on these results, KLHL29 insertion polymorphism may represent a normal polymorphic event that occurred in the process of human evolution, unrelated to carcinogenesis. Nevertheless, this conclusion needs to be confirmed by analyzing a larger number of samples from other countries.
The majority of genomic insertions of DNA fragments accumulate sequence substitutions and are not ultimately activated. Nevertheless, some insertions, especially repetitive transposable elements, develop new transcripts due to interaction with proximal genes, thus providing a transcription start site, polyadenylation site, or alternative splice site. 33 Novel transcripts also are derived from nonrepetitive intronic genomic insertions by mechanisms similar to those shown for repeats. [33] [34] [35] In the current study, because the insertion presumably was copied from intron 4 of the NR5A2 gene to intron 1 of KLHL29, a new KLHL29 antisense transcript in the same orientation to the NR5A2 sense strand was identified by RNA-Seq data and validated in various clinical samples. Perhaps a polyadenylation signal in the inserted NR5A2 sequence contributed to the generation of this novel alternative transcript (NR5A2-KLHL29FT). The new transcript was only transcribed from KLHL29 genes containing an insertion sequence. It is interesting to note that because expression of NR5A2-KLHL29FT is lower in colon cancers than in matched normal tissues, we hypothesize that NR5A2-KLHL29FT may participate in the origin or progression of colon cancer. However, the precise mechanism and experimental validation require further study. Furthermore, because the orientation of the NR5A2 insertion is in the antisense direction relative to the sense direction of the KLHL29 gene, we reason that if the KLHL29 intron 1 is spliced out in the proper expected manner, this NR5A2 insertion will be removed. In this case, no novel fusion protein will be produced, because the alien sequence will have been removed during RNA splicing. However, because the insertion is located only 175 bp away from exon 2, it is conceivable that it may exert an effect on intron-exon splicing at this junction. Additional possible but unproven effects include the presence of cryptic DNA sequences containing an alternate promoter, a transcriptional enhancer element, or a motif affecting mRNA stability or molecular half-life. Thus, although there is no proven mechanism for this 121-base DNA insertion to alter the expression or function of the KLHL29 protein, this possibility still cannot be ruled out.
Therefore, this insertion still may be functionally involved in the development or progression of colon cancer. It is interesting to note that many other details remain unanswered, including the full length of the new transcript, the exact genomic DNA splice site, and the exact mechanism leading to the generation of the new transcript. We will continue to study these areas to clearly elucidate the function of the new transcript (NR5A2-KLHL29FT) in future studies. Meanwhile, transchromosomal insertions similar to the insertion at the KLHL29 locus are not fully recognized, perhaps because they always fool the aligners as recognizing them as chromosome rearrangements in whole-genome sequencing. Thus, during clinical validation of novel FTs identified by RNA-Seq, we should realize that similar FTs may be transcribed from transchromosomal insertions that are not correctly annotated in current genome databases as an alternative to chromosome rearrangement.
In summary, a novel transcript (NR5A2-KLHL29FT) was identified by RNA-Seq and validated in colonic tissue samples. However, preliminary data suggest that NR5A2-KLHL29FT is transcribed from a polymorphic insertion at the KLHL29 locus, rather than a chromosomal rearrangement between chromosomes 1 and 2. This polymorphic insertion does not appear to be related to colon cancer risk. However, preliminary data suggest that NR5A2-KLHL29FT may participate in the origin or progression of colon cancer. Further studies are needed to elucidate the precise function of NR5A2-KLHL29FT in colorectal and other cancers.
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